Literature DB >> 35895134

Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease.

Yun Su1,2,3, Changhe Shi1,3, Tai Wang4, Chen Liu1,3, Jing Yang1,3, Shuyu Zhang5, Liyuan Fan1,2,3, Huimin Zheng1,2,3, Xinwei Li1,2,3, Haiyang Luo1,2,3, Shuo Zhang1,2,3, Zhengwei Hu1,2,3, Yu Fan1,3, Xiaoyan Hao1,3, Chenglin Zhang2,6, Bo Song1,3, Chengyuan Mao7,8,9,10, Yuming Xu11,12,13.   

Abstract

BACKGROUND AND OBJECTIVES: Mounting evidence indicates the involvement of the innate immune system in Parkinson's disease (PD). Nevertheless, the implications of peripheral monocytes have not been fully elucidated. Although alpha-synuclein (α-synuclein) has been described as a pathological hallmark of PD, the proinflammatory effect of α-synuclein on monocytes is understudied. This study aimed to comprehensively characterize peripheral monocytes in PD patients and to investigate the proinflammatory magnitude of fibrillar α-synuclein.
METHODS: Using flow cytometry, we explored the distribution of monocytic subpopulations. We also investigated the actions of peripheral monocytes in response to lipopolysaccharides (LPS) and to fibrillar α-synuclein stimuli by measuring inflammatory molecule levels in post-culture supernatants.
RESULTS: Classical monocytes were enriched, in parallel with lower proportions of intermediate and nonclassical monocytes in patients with PD than in controls. Lower levels of TNF-α and IL-6 were spontaneously produced by unstimulated monocytes in patients with PD. LPS and fibrillar α-synuclein stimuli induced high levels of TNF-α, IL-1β, IL-6, and sCD163 in the PD and control groups. Strikingly, the fold induction of TNF-α and IL-6 was lower in patients with PD than that in normal controls under the same stimulation.
CONCLUSION: Our results revealed a strong dysregulation of peripheral monocytes in PD patients, including subpopulation shifts and impaired response to specific stimuli, and the proinflammatory effect of α-synuclein on monocytes. Further studies are needed to clarify the specific mechanisms by which these immunological abnormalities are present in PD to open the possibility of immunoregulatory therapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Alpha-synuclein; Innate immune system; Parkinson’s disease; Peripheral monocytes

Year:  2022        PMID: 35895134     DOI: 10.1007/s00415-022-11258-w

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  45 in total

1.  Microglial activation and dopamine terminal loss in early Parkinson's disease.

Authors:  Yasuomi Ouchi; Etsuji Yoshikawa; Yoshimoto Sekine; Masami Futatsubashi; Toshihiko Kanno; Tomomi Ogusu; Tatsuo Torizuka
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

2.  Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study.

Authors:  Tatsuhiro Terada; Masamichi Yokokura; Etsuji Yoshikawa; Masami Futatsubashi; Satoshi Kono; Takashi Konishi; Hiroaki Miyajima; Takanori Hashizume; Yasuomi Ouchi
Journal:  Ann Nucl Med       Date:  2016-06-14       Impact factor: 2.668

3.  Association of Parkinson disease with structural and regulatory variants in the HLA region.

Authors:  William T Wissemann; Erin M Hill-Burns; Cyrus P Zabetian; Stewart A Factor; Nikolaos Patsopoulos; Bryan Hoglund; Cherie Holcomb; Ryan J Donahue; Glenys Thomson; Henry Erlich; Haydeh Payami
Journal:  Am J Hum Genet       Date:  2013-10-31       Impact factor: 11.025

4.  Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.

Authors:  Cornelis Blauwendraat; Karl Heilbron; Costanza L Vallerga; Sara Bandres-Ciga; Rainer von Coelln; Lasse Pihlstrøm; Javier Simón-Sánchez; Claudia Schulte; Manu Sharma; Lynne Krohn; Ari Siitonen; Hirotaka Iwaki; Hampton Leonard; Alastair J Noyce; Manuela Tan; J Raphael Gibbs; Dena G Hernandez; Sonja W Scholz; Joseph Jankovic; Lisa M Shulman; Suzanne Lesage; Jean-Christophe Corvol; Alexis Brice; Jacobus J van Hilten; Johan Marinus; Johanna Eerola-Rautio; Pentti Tienari; Kari Majamaa; Mathias Toft; Donald G Grosset; Thomas Gasser; Peter Heutink; Joshua M Shulman; Nicolas Wood; John Hardy; Huw R Morris; David A Hinds; Jacob Gratten; Peter M Visscher; Ziv Gan-Or; Mike A Nalls; Andrew B Singleton
Journal:  Mov Disord       Date:  2019-04-07       Impact factor: 10.338

5.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

Authors:  Alexander Gerhard; Nicola Pavese; Gary Hotton; Federico Turkheimer; Meltem Es; Alexander Hammers; Karla Eggert; Wolfgang Oertel; Richard B Banati; David J Brooks
Journal:  Neurobiol Dis       Date:  2005-09-21       Impact factor: 5.996

6.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.

Authors:  Taye H Hamza; Cyrus P Zabetian; Albert Tenesa; Alain Laederach; Jennifer Montimurro; Dora Yearout; Denise M Kay; Kimberly F Doheny; Justin Paschall; Elizabeth Pugh; Victoria I Kusel; Randall Collura; John Roberts; Alida Griffith; Ali Samii; William K Scott; John Nutt; Stewart A Factor; Haydeh Payami
Journal:  Nat Genet       Date:  2010-08-15       Impact factor: 38.330

7.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Authors:  Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton
Journal:  Nat Genet       Date:  2014-07-27       Impact factor: 38.330

8.  Abnormalities of age-related T cell senescence in Parkinson's disease.

Authors:  C H Williams-Gray; R S Wijeyekoon; K M Scott; S Hayat; R A Barker; J L Jones
Journal:  J Neuroinflammation       Date:  2018-05-28       Impact factor: 8.322

Review 9.  Periphery and brain, innate and adaptive immunity in Parkinson's disease.

Authors:  Ashley S Harms; Sara A Ferreira; Marina Romero-Ramos
Journal:  Acta Neuropathol       Date:  2021-02-08       Impact factor: 17.088

Review 10.  Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.

Authors:  Xiao-Yan Qin; Shu-Ping Zhang; Chang Cao; Y Peng Loh; Yong Cheng
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

View more
  1 in total

1.  Single-cell RNA sequencing of CSF reveals neuroprotective RAC1+ NK cells in Parkinson's disease.

Authors:  Qing Guan; Wei Liu; Ketao Mu; Qi Hu; Jiazhao Xie; Liming Cheng; Xiong Wang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.